Chronic Liver Disease – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Chronic Liver Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Chronic liver disease is a progressive decline in liver functions, encompassing crucial roles such as clotting factor and protein production, detoxification, and bile excretion. It involves a continual cycle of inflammation, destruction, and regeneration of liver parenchyma, culminating in fibrosis and cirrhosis. Cirrhosis, the advanced stage, disrupts liver architecture, creating nodules, reorganizing vasculature, inducing neo-angiogenesis, and depositing extracellular matrix. The cellular mechanism involves stellate cell and fibroblast recruitment, leading to fibrosis, while hepatic stem cells play a pivotal role in parenchymal regeneration. Understanding this complex process is essential for effective management of chronic liver diseases.
The Chronic Liver Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Chronic Liver Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Liver Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Chronic Liver Disease | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 17 molecules, with 16 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Chronic Liver Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Chronic Liver Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Chronic Liver Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Andalusian Public Foundation Progress and HealthBiostax Corp
Genesen Co Ltd
HepaRegeniX GmbH
Hepatx Corp
HighTide Therapeutics Inc
LinXis BV
PrimeGen Global Inc
RAGE Biotech Pty Ltd
Resolution Therapeutics Ltd
Shionogi & Co Ltd
Suzhou Regend Therapeutics Co Ltd
Swedish Orphan Biovitrum AB
Trevi Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Chronic Liver Disease reports